ClinicalTrials.gg
Active, not recruitingNCT04965792Updated Jun 18, 2026

Post-treatment Surveillance in HPV+ Oropharyngeal SCC

An observational study in HPV and Oropharyngeal Squamous Cell Carcinoma, sponsored by Dana-Farber Cancer Institute. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by Dana-Farber Cancer Institute · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 24 studies in Squamous Cell Carcinoma of Head and Neck by Dana-Farber Cancer Institute — 3 open to participants now, 5 under way, none of them phase 3. Squamous Cell Carcinoma of Head and Neck · Dana-Farber Cancer Institute.

Started
2020
with 1 other
Observational
Only one
of the 24
Registered
20th of 24
by date

Among the 24 studies in Squamous Cell Carcinoma of Head and Neck by Dana-Farber Cancer Institute, this one is one of 2 that started in 2020, is the only observational one, and was the 20th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

3 of the 24 studies in Squamous Cell Carcinoma of Head and Neck by Dana-Farber Cancer Institute are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Squamous Cell Carcinoma of Head and Neck by Dana-Farber Cancer Institute, or all of them as a file.
02

Study summary

In this research study the investigators are examining a blood test to detect HPV DNA in the blood that can possibly detect cancer recurrence earlier than with standard surveillance measures.

Read the detailed description

This research study involves blood tests to detect HPV DNA at regular time points after treatment for HPV-positive oropharyngeal squamous cell carcinoma (HPV-OPC). Participants may undergo scans based on the results of the blood tests. Study participants will also be asked to complete quality of life questionnaires periodically.

Participation in this study may last for up to 3 years. It is expected that about 150 people will take part in this research study.

03

Conditions studied

  • HPV
  • Oropharyngeal Squamous Cell Carcinoma

Keywords

  • HPV
  • Oropharyngeal Squamous Cell Carcinoma
  • HPV + Oropharyngeal Squamous Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Individuals with HPV-positive oropharynx cancer undergoing curative-intent treatment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have or cytologically confirmed incident or recurrent squamous cell carcinoma of the tonsil or base of tongue (oropharynx) - includes of any lymph node with clinical evidence of an oropharynx tumor (unknown primary carcinoma in an involved cervical neck lymph node is permitted if high-risk HPV testing is positive on the involved node)
  • HPV-associated tumor as defined by one or more : positive p16 immunohistochemistry (>70%) OR in situ hybridization OR PCR-based methods
  • Age 18 years or older
  • Will undergo oropharyngeal cancer treatment with curative intent
  • Ability to understand and the willingness to sign a written document.
  • Baseline positive or detectable ctHPV DNA result in plasma OR detectable corresponding HPV DNA in tumor tissue prior to treatment

Exclusion criteria

Exclusion Criteria:

  • Distant disease (M1, AJCC 8th edition)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • HPV-positive oropharyngeal squamous cell carcinoma (HPV-OPC) Patients

    Newly diagnosed HPV-positive oropharyngeal squamous cell carcinoma (HPV-OPC) patients will undergo blood testing for circulating tumor HPV DNA.

    Other: Screening

Interventions

  • OtherScreening

    Blood test

06

What researchers measure

Primary outcomes

  1. Recurrent disease Rate

    The proportion of patients with recurrence first detected by ctHPV DNA will be calculated as a percentage and 95% confidence intervals (CI) established using binomial exact calculation.

    Time frame: Up to 5 years

Secondary outcomes

  1. Recurrence Detection Predictive Properties

    Estimate positive and negative predictive value, sensitivity and specificity of ctHPV DNA for subsequent diagnosis of recurrent HPV-OPC

    Time frame: Time from first positive ctHPV DNA test to diagnosis of recurrence, assessed up to 5 years

  2. Time to diagnosis of recurrence

    The median (IQR) number of months between the first positive ctHPV DNA test to definitive diagnosis of recurrence will be calculated.

    Time frame: Time from first positive ctHPV DNA test to confirmed diagnosis of recurrence, assessed up to 5 years

  3. Progression-free survival (PFS)

    Calculated using Kaplan Meier method

    Time frame: Time from registration to the earlier of progression or death due to any cause, assessed up to 5 years

  4. Overall survival (OS)

    Calculated using Kaplan Meier method

    Time frame: Time from registration to death due to any cause, or censored at date last known alive, assessed up to 5 years

  5. Quality of Life (QOL)

    QOL will be evaluated using the by Fear of Recurrence Questionnaire-Short Form (score range 6-40; lower score is lower fear of recurrence) and EQ-5D-5L questionnaire (5 questions with score range 1-5 where higher score is worse; and one question with score range 0-100 where higher is better).

    Time frame: Pre-study, at 3 and 6 months, then at every other visit for the duration of the study up to 5 years

  6. Cost Comparison

    Projected cost of ctHPV DNA-based compared with standard surveillance

    Time frame: Up to 5 years

07

Study locations

1 site
08

References and documents

Publications

  • Rettig EM, Schoenfeld JD, Miller J, Sargent B, Carey E, Margalit DN, Sehgal K, Sethi RKV, Uppaluri R, Tishler RB, Goguen LA, Annino DJ, Sim ES, Jo VY, Wong KS, Guenette JP, Haddad RI, Hanna GJ. A Prospective Trial of Biomarker-Guided Surveillance for HPV-Positive Oropharynx Cancer Using Plasma Tumor Tissue-Modified Viral HPV DNA. Clin Cancer Res. 2025 May 1;31(9):1605-1614. doi: 10.1158/1078-0432.CCR-24-3053. PubMed 39715483 ↗

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data can be shared no earlier than 1 year following the date of publication

Access criteria: Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu Contact the Partners Innovations team at http://www.partners.org/innovation

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2020 (actual). Primary completion is estimated for Nov 2026, 72 months after the start.

Of 107 non-industry observational studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 77 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 132. This study's planned 72 months is close to that.

Counting every sponsor, half of 117 studies reached it within 77 months; a quarter within 26 and three quarters within 132.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2021
First posted
Jul 16, 2021
StartActual
Nov 19, 2020
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2027
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04965792
Responsible party
Eleni Marie Rettig, MD (Principal Investigator, Dana-Farber Cancer Institute) — Principal investigator
First posted
Jul 16, 2021
Start date
Nov 19, 2020
Primary completion
Nov 2026 (estimated)
Completion
Nov 2027 (estimated)
Last update
Jun 18, 2026

Study contacts

Eleni M Rettig, MD
principal investigator · Brigham and Women's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion